Trinity Life Sciences Enhances HTA Vision with Generative AI
WALTHAM, Mass. – March 11, 2025 – Trinity Life Sciences, a leading provider of strategy, insights, and analytics for the life sciences sector, has announced an enhancement to its HTA Vision offering. This upgrade introduces generative AI (GenAI) capabilities to quickly extract and summarize critical information from health technology assessments (HTAs). The goal is to streamline the information-gathering process for any therapeutic area or drug class.
HTA Vision aims to transform complex documents into clear, comprehensive overviews. This is especially important because HTA outcomes are often extensive and intricate documents that require rapid interpretation by Global Market Access leaders in life sciences. These leaders then use the insights to inform day-to-day decision-making. The enhancement combines AI with human expertise to offer tailored interpretations and deep insights into how health authorities evaluate new products.
“Especially in the EU, market standards and complexities are increasing, which is making the environment more challenging for pharma,” said Monica Martin de Bustamante, Senior Partner and Head of Advisory at Trinity Life Sciences. “Combining artificial intelligence with human expertise streamlines and simplifies payer decision analysis without losing the tailored interpretations and deep insights from experts on how health authorities are evaluating products.”
Max Hunt, a Partner in Trinity Life Sciences’ Evidence, Value, Access & Pricing practice, added, “Strategic decisions for clinical development and evidence generation are made by life sciences leaders on a daily basis and need to be informed by the latest market intelligence. Trinity HTA Vision allows users to position themselves for success in a global payer landscape that can be fickle and demanding—the addition of GenAI provides users with insights on HTA drivers at their fingertips.”
Trinity HTA Vision
Trinity HTA Vision provides custom solutions offering timely, strategic market access insights and interpretation of payer decisions globally. These solutions include a cloud-based HTA dashboard with GenAI, flash alerts, HTA decision digests, and reports on key events. The system provides insights curated by experts with extensive knowledge of life sciences commercialization and global HTA, delivering flexible, scalable solutions customized for each client’s needs.
Virtual Demo: HTA Vision with GenAI
A virtual demo of HTA Vision with GenAI will be held on March 13th. Trinity’s value, access, and pricing experts, Max Hunt and Andreia Ribeiro, will be demonstrating the GenAI capabilities and discussing how this cutting-edge technology complements expert analysis.
Life sciences executives can register for the virtual demo.
About Trinity Life Sciences
With nearly 30 years of experience, a specialized team, and access to data and analytics, Trinity Life Sciences collaborates with companies in the life sciences industry to provide strategic insights. They use a combination of strategy, insights, and analytics to assist life science executives with their clinical and commercial decision-making processes. Learn more about how Trinity is driving evidence to action by visiting TrinityLifeSciences.com.
